MYELOPROLIFERATIVE NEOPLASMS IN BUDD-CHIARI SYNDROME AND PORTAL VEIN THROMBOSIS: A META-ANALYSIS

RUNNING TITLE: MPNs in BCS and PVT

Jasper H. Smalberg¹, Lidia R. Arends² ³, Dominique C. Valla⁵, Jean-Jacques Kiladjian⁶, Harry L.A. Janssen⁷, Frank W.G. Leebeek¹

¹Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; ²Institute of Psychology, Erasmus University Rotterdam, Rotterdam, the Netherlands; ³Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands; ⁴Institute of Pedagogical Sciences, Erasmus University Rotterdam, Rotterdam, The Netherlands. ⁵Service d'Hépatologie, Hôpital Beaujon, Clichy, France; ⁶APHP, Hopital Saint-Louis, Centre d’Investigations Cliniques, Paris, France; ⁷Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Corresponding author:
Prof. Dr. F.W.G. Leebeek, Department of Hematology, University Medical Center Rotterdam, Room L-438, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
E-mail: f.leebeek@erasmusmc.nl. Phone: +31 10 7031672 Fax: +31 10 7035814

Key words: Budd-Chiari syndrome; portal vein thrombosis; myeloproliferative neoplasm; JAK2V617F; JAK2 exon 12; MPL515; polycythemia vera; essential thrombocytosis.
ABSTRACT

Myeloproliferative neoplasms (MPNs) are the most common cause of Budd-Chiari syndrome (BCS) and non-malignant, non-cirrhotic portal vein thrombosis (PVT). In this meta-analysis we determined the prevalence of MPNs and their subtypes as well as JAK2V617F and its diagnostic role in these uncommon disorders. MEDLINE and EMBASE databases were searched. Prevalence of MPNs, JAK2V617F and MPN subtypes were calculated using a random-effects model. A total of 1,062 BCS and 855 PVT patients were included. In BCS, mean prevalence of MPNs and JAK2V617F was 40.9% (95% CI: 32.9%–49.5%) and 41.1% (95%CI: 32.3%–50.6%), respectively. In PVT, mean prevalence of MPNs and JAK2V617F was 31.5% (95% CI: 25.1%–38.8%) and 27.7% (95%CI: 20.8%–35.8%), respectively. JAK2V617F and MPNs were more frequent in BCS compared to PVT (P=.03 and P=.09, respectively). Polycythemia vera was more prevalent in BCS than in PVT (P=.001). JAK2V617F screening in SVT patients without typical hematological MPN features identified MPN in 17.1% and 15.4% of screened BCS and PVT patients, respectively. These results demonstrate a high prevalence of MPNs and JAK2V617F in SVT patients and show differences in underlying etiology between these disorders. Furthermore, these results validate routine inclusion of JAK2V617F in the diagnostic work-up of SVT patients.
INTRODUCTION

Splanchnic vein thrombosis (SVT) includes the Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT). Primary BCS is characterized by thrombosis of the hepatic veins and/or the suprahepatic inferior vena cava, resulting in obstruction of the hepatic venous outflow tract. A distinct disorder that also includes the liver vasculature is portal vein thrombosis (PVT), which often occurs in association with local factors such as liver cirrhosis or malignancy. PVT in the absence of liver cirrhosis or local malignancy is less frequently encountered and shows a considerable overlap in etiology with primary BCS. In this meta-analysis, we will focus exclusively on primary BCS and non-malignant, non-cirrhotic PVT.

Philadelphia-negative myeloproliferative neoplasms (MPNs) are the most frequent underlying prothrombotic factor in BCS and PVT, with a reported prevalence of 30-50% and 15-30%, respectively. Peripheral blood cell counts often remain within a normal range, due to portal hypertension and its sequelae (splenomegaly, hemodilution, iron deficiency). Despite suggestive features of an MPN, fulfilment of usual diagnostic criteria can therefore often be lacking, which is a notorious problem in MPN diagnostics in these patients. The term occult MPN has been used in the literature for patients who lack these typical hematological features of MPN, but who harbour clear features of MPN, for example by means of bone marrow (BM) biopsy findings and growth of erythroid colonies in the absence of exogenous erythropoietin, referred to as spontaneous endogenous erythroid colonies (EEC), both of which have several limitations. BM biopsy is invasive and the distinction between MPN and reactive BM is not unambiguous. EEC assays are performed only in specialized centers, are difficult to standardize and the possibility of false positives in nonclonal causes of erythrocytosis and healthy controls.

The discovery of the JAK2V617F gain-of-function mutation in 2005, found in 95% of patients with polycythemia vera (PV) and in about 50% of patients with essential thrombocythemia (ET) and myelofibrosis (MF), represented a crucial advance in the diagnostic approach to MPNs. The close relationship between MPNs and BCS and PVT
was confirmed by the high frequency of JAK2V617F among these patients, present in 30-
45%\textsuperscript{4,9,20} and 17-35%,\textsuperscript{11,20,21} respectively. Interestingly, JAK2V617F screening offered a new
diagnostic tool to detect these so-called occult MPNs in SVT patients, as this mutation was
frequently demonstrated in SVT patients without characteristic elevated peripheral blood
counts.\textsuperscript{22} JAK2V617F screening has since become part of the standard diagnostic work-up in
SVT.

Other advances in the field of MPNs were the identification of the MPL515 mutations
in the thrombopoietin receptor gene in approximately 5 and 10% of patients with JAK2V617F
negative ET and MF, respectively, and JAK2 exon 12 mutations in less than 5% of
JAK2V617F negative PV patients.\textsuperscript{23-27} Both mutations have been described in small numbers
of SVT patients, but their clinical relevance has not yet been fully clarified.\textsuperscript{28,29}

The aims of this study were 1) to assess the prevalence of MPNs and JAK2V617F in
BCS and PVT patients; 2) to determine the frequency of MPN subtypes in BCS and PVT
patients; 3) to determine JAK2V617F prevalence in in BCS and PVT patients without typical
hematological features of MPN, and; 4) to evaluate the clinical relevance of the MPL and
JAK2 exon 12 mutations in BCS and PVT patients.

METHODS

Search strategy and selection criteria
One of the authors (J.S.) searched Ovid MEDLINE and EMBASE from 1980 to August 1\textsuperscript{st}
2011. The search strategy was restricted to published data and the English language using
the subject headings presented in the appendix. The search was supplemented by manually
reviewing the reference list of retrieved articles and relevant reviews. Titles and abstracts of
retrieved citations were screened and potentially suitable studies were read in full by J.S. and
F.L. Studies were selected when the following criteria were met: 1) patients were diagnosed
with primary BCS or non-cirrhotic, non-malignant PVT, or patients with an underlying
malignancy or cirrhosis were explicitly mentioned; 2) information on MPNs and/or
JAK2V617F, JAK2 exon 12 or MPL515 was provided; 3) the cohort consisted of patients in which patients with established MPNs or other thrombophilic factors were not excluded; 4) splanchnic vein thrombosis was subdivided in BCS and PVT; 5) a minimum of ten patients were included. Disagreements were resolved after discussion or after having collected the opinion of a third reviewer (H.J.).

Data extraction
J.S. extracted data on each selected study (year of publication, study design, demographics, criteria for diagnosing MPNs, number of patients included). Patients with BCS in the presence of a malignancy and PVT patients with a malignancy or cirrhosis were excluded from the analysis. Patients with combined BCS and PVT were classified as BCS according to common practice. MPNs were defined according to the diagnostic criteria used in the included studies. Different diagnostic criteria, mostly World Health Organization or Polycythemia Vera Study Group criteria, were used in the various studies. JAK2V617F, being discovered in 2005, was only reported in studies published after this date and was almost invariably presented as a separate entity, rather than being integrated in MPN work-up as is now customary. We therefore extended MPN work-up of these studies as follows. JAK2V617F was considered pathognomonic for MPN and patients that did not meet the diagnostic criteria for MPN but were found JAK2V617F positive, were classified as MPN. MPN subtypes were classified according to the diagnostic criteria used in each study. If high clinical suspicion based on typical hematological features (i.e. clinical, laboratory and/or morphological) of MPN existed in patients with JAK2V617F, but insufficient criteria for a specific subtype was met, the patient was classified as MPN unclassifiable. If JAK2V617F was present, but clinical, laboratory and/or morphological data were insufficiently collected, patients were designated as solitary JAK2V617F positive MPN. Studies that did not report on JAK2V617F were only included in the MPN subtype analysis and not in the MPN prevalence analysis as this would result in an underestimation of MPN prevalence. Corresponding
authors were contacted in case essential data were not mentioned, with a reminder sent after two weeks.

**Statistical analysis**

Weighted mean proportion and 95% confidence intervals (CI) of MPNs, \( JAK2^{V617F} \), and MPN subtypes prevalence were calculated using a random effects model. Differences in prevalence were calculated by means of Pearson’s chi square. All statistical tests were two-sided and \( P \)-values < .05 were considered statistically significant. Statistical heterogeneity was evaluated using the \( I^2 \) statistic, which describes the percentage of variation across studies that is due to heterogeneity rather than chance, with a \( P \)-value < .05 representing statistically significant heterogeneity. If heterogeneity was present, the analyses were repeated removing one study a time to identify the source of heterogeneity. All analyses were performed with Comprehensive Meta Analysis 2.2 for Windows (Biostat, Englewood, USA) and the overall effects are presented as event rates with 95% CI.

**RESULTS**

**Study identification and selection**

We identified 822 potentially relevant publications: 256 from MEDLINE and 566 from EMBASE. A total of 109 studies were duplicate, and 665 studies were excluded after title and abstracts screening according to predefined inclusion criteria. The remaining studies were retrieved in full for detailed evaluation. Five additional studies were identified from reference lists. Figure 1 shows the study selection process.

Of the 53 retrieved studies, 21 were excluded because of the following reasons: in two studies patients with malignancies or liver cirrhosis were not excluded or explicitly mentioned,\(^{30,31}\) five studies were based on selected cohorts in which patients with established MPNs or other thrombophilic factors were excluded,\(^{32-36}\) one study did not differentiate SVT into BCS and PVT,\(^{37}\) in four studies MPN criteria were not acceptable or
unclear,\textsuperscript{14,38-40} and two studies included less than 10 patients.\textsuperscript{29,41} In addition, seven studies contained duplicate data.\textsuperscript{42-48} This resulted in 32 studies eligible for inclusion.

\textit{Study characteristics and quality}

Table 1 and 2 summarizes the characteristics of the included studies for BCS and PVT, respectively. Study size ranged between 10 and 237 patients. Nineteen studies including 1,062 patients reported on MPNs and/or the \textit{JAK2}V617F mutation in BCS patients. Fifteen studies including 855 patients reported on MPNs and/or the \textit{JAK2}V617F mutation in PVT patients. Three studies including 268 patients reported on \textit{JAK2} exon 12 mutations.\textsuperscript{20,28,49} Two studies including 305 patients reported on \textit{MPL}515 mutations.\textsuperscript{20,28} Five studies included a healthy control population,\textsuperscript{21,47,50-52} all other studies were essentially retrospective cohort studies. Nineteen of these studies enrolled patients consecutively.\textsuperscript{2,4,5,7-9,11,12,21,28,52-61} Studied populations partly overlapped in nine publications (i.e. to some extent duplication of patients).\textsuperscript{2,5-7,9,14,20,47,62}

\textit{MPNs and JAK2V617F in Budd-Chiari syndrome}

A total of 1,062 BCS patients were included in the analysis. Of these patients, 440 underwent a complete diagnostic work-up for MPN including both clinical, laboratory and/or morphological features of MPN as well as \textit{JAK2}V617F mutation analysis. MPN was present in 40.9\% (95\% CI: 32.9\%–49.5\%) of these patients. Of the MPN patients, 80.3\% were \textit{JAK2}V617F positive (95\%CI: 63.5\%–90.5\%). The \textit{JAK2}V617F mutation was present in 159 of 401 tested patients, for a mean prevalence of 41.1\% (95\% CI: 32.3\%–50.6\%). \textit{JAK2}V617F screening in patients without typical hematological features of MPN yielded diagnosis of MPN in 17.1\% (95\%CI: 7.9\%–33.3\%). Distribution of MPN subtypes was as follows: PV, ET, MF, unclassifiable MPNs and solitary \textit{JAK2}V617F positive MPNs in 52.9\% (95\%CI: 42.2\%–63.4\%), 24.6\% (95\%CI: 18.0\%–32.5\%), 6.7\% (95\%CI: 3.7\%–11.9\%), 17.0\% (95\%CI: 9.8\%–27.9\%) and 6.5\% (95\%CI: 2.4\%–16.3\%), respectively (supplementary figure online).
Four studies made a distinction between diagnosis of MPN prior or simultaneous to BCS, in which 13 out of 50 patients were diagnosed with MPN prior to BCS, whereas BCS was the presenting symptom of MPN in 37 out of 50 patients. Follow-up of JAK2V617F-positive MPNs without typical hematological MPN features was provided in three publications, in which 11 out of 28 patients (41%) developed characteristic laboratory or morphological features of MPN, ranging from 0.7 to seven years after diagnosis of BCS.

**MPNs and JAK2V617F in portal vein thrombosis**

A total of 855 PVT patients were included in the analysis. MPNs were present in 188 out of 615 or 31.5% (95% CI: 25.1%–38.8%) of the patients who underwent complete diagnostic work-up for MPN including both clinical, laboratory and/or morphological features of MPN as well as JAK2V617F mutation analysis. Of the MPN patients, 86.6% were JAK2V617F positive (95% CI: 73.1%–93.9%). The JAK2V617F mutation was present in 166 of 595 tested patients, for a mean prevalence of 27.7% (95% CI: 20.8%–35.8%). JAK2V617F mutation analysis yielded diagnosis of MPN in 15.4% (95%CI: 7.9%–33.3%) of screened PVT patients without characteristic hematological features of MPN, that would otherwise have been undiagnosed. Distribution of MPN subtypes was as follows: PV, ET, MF, unclassifiable MPNs and solitary JAK2V617F positive MPNs in 27.5% (95%CI: 19.0%–38.1%), 26.2% (95%CI: 19.1%–34.8%), 12.8% (95%CI: 8.0%–19.9%) and 17.7% (95%CI: 9.9%–29.7%), and 24.0% (95%CI: 11.5%–43.3%), respectively (supplementary figure online).

Five studies differentiated between diagnosis of MPN prior or simultaneous to PVT diagnosis, showing that 17 out of 64 patients were diagnosed with MPN prior to PVT, whereas PVT was the presenting symptom of MPN in 47 out of 64 patients. Follow-up of JAK2V617F positive MPNs without typical MPN features counts was provided in four publications in which six out of 48 patients (13%) developed characteristic laboratory or morphological features of MPN, ranging from one to ten years after diagnosis of PVT.

One study described the long-term follow-up of 44 PVT patients with an underlying MPN.
Five PV and two ET patients developed secondary MF, three patients with MF progressed to end-stage MF, and four patients developed acute myeloid leukemia after a median period of 9.7 years (range 1–17) following MPN diagnosis. Twenty-nine and 18% of the deaths in this cohort were attributable to end-stage MF and progression to acute myeloid leukemia, respectively.

**JAK2 exon 12 and MPL515 mutations in splanchnic venous thrombosis**

A total of 268 SVT patients (ratio BCS/PVT unknown) were tested for JAK2 exon 12 and 305 for MPL515 mutations. Three of these patients were found to carry MPLW515K mutation. The JAK2 exon 12 mutation was not present in any of these patients.

**Differences between BCS and PVT**

Prevalence of JAK2V617F and MPNs was higher in BCS than in PVT (P = .03 and P = .09, respectively). With regards to the subtype analysis, prevalence of PV and MF was higher in BCS than in PVT patients (P = .001 and P = .09, respectively). Prevalence of solitary JAK2V617F positive MPNs was higher in PVT compared to BCS (P = .03). There was no difference between the prevalence of ET and MPNs unclassifiable (P = .77 and P = .92, respectively). There was no difference in identification rate of MPNs without typical features by means of JAK2V617F between the two disorders (17.1% vs. 15.4%, P = .68). All analyses were repeated including only publications since 2005 and excluding papers with potentially duplicated inclusion of patients, which showed the same results (data not shown).

**I² and heterogeneity amongst studies**

A considerable heterogeneity amongst the studies was observed (P < .05). We therefore performed an additional analysis in which we excluded one study per analysis. This analysis showed that no single study significantly affected the point estimate of MPNs, JAK2V617F and its subtypes in both BCS and PVT.
DISCUSSION

In this meta-analysis we assessed the role of MPNs in the etiology of primary BCS and non-malignant, non-cirrhotic PVT. The results showed a higher prevalence of MPNs and JAK2V617F in BCS compared to PVT patients. Interestingly, our results indicate a difference in the distribution of underlying MPN subtype between BCS and PVT patients, PV being the most frequent MPN in BCS. Finally, MPL515 mutations were present in less than 1% of BCS and PVT series, whereas JAK2 exon 12 mutations have never been published so far in SVT patients.

Two meta-analyses have previously evaluated the impact of the JAK2V617F mutation in SVT patients. In 2009, Dentali et al assessed the role of JAK2V617F in patients with various venous thrombosis, including SVT, deep vein thrombosis of the lower extremities or pulmonary embolism, cerebral vein thrombosis and retinal vein thrombosis. In this study, a remarkable high prevalence of JAK2V617F in SVT was reported, whereas its prevalence in other forms of VTE was similar to that of the general population. SVT was not subdivided into BCS and PVT which impedes comparison of MPNs and JAK2V617F prevalence between the two disorders. Qi et al calculated the prevalence of JAK2V617F in BCS and PVT separately, and assessed its prevalence after exclusion of cases with pre-existing MPNs. In contrast to those previously published studies, we set out to provide a complete overview of MPNs in the etiology of BCS and PVT. This included assessment of the prevalence of MPNs and JAK2V617F, as well as the prevalence of MPN subtypes. In addition, we have compared BCS and PVT for each of these variables, as it is increasingly recognized that, despite several similarities, risk profiles are different between these patients. To achieve this goal, we have assessed all the publications regarding MPNs in SVT since 1980.

The results of this meta-analysis indicate a high prevalence of MPNs in patients with SVT. The strong relation between MPNs and SVT is confirmed by the high prevalence of JAK2V617F in these patients. Interestingly, JAK2V617F and MPNs were more prevalent in BCS compared to PVT patients, the latter showing a statistical trend rather than a significant
difference. This difference may be partially explained by the more prominent role of local risk factors, such as focal inflammatory lesions and injury to the portal venous system, in the development of PVT.\textsuperscript{68} This might contribute to the relatively limited role of general prothrombotic conditions reported in the etiology of PVT. Why MPNs and JAK2\textsuperscript{V617F} are so strongly related to thrombosis of the splanchnic veins remains an unresolved issue. Further research is needed to identify associated factors that could be involved in the pathogenesis of thrombosis at these specific sites. In this respect, it has been speculated that endothelial cells of the splanchnic veins may interact with activated platelets and/or leukocytes and increased microparticles, which are characteristic features of MPNs.\textsuperscript{69} In addition, these endothelial cells have been shown to carry the JAK2\textsuperscript{V617F} mutation and could be part of the malignant process.\textsuperscript{70}

We observed a marked difference between BCS and PVT patients regarding the distribution of MPN subtypes. PV was clearly more common in BCS compared to PVT. The prothrombotic effect of high hematocrit values in PV is well established.\textsuperscript{71} Under low-shear conditions, such as in the venous circulation, a high hematocrit has a more important impact on blood viscosity and causes a major disturbance to blood flow.\textsuperscript{72,73} This mechanism may be mediated by the interaction between adhesion molecules and red blood cells. Wautier et al described an increased adhesiveness of red blood cells in PV to human umbilical vein endothelial cells and elegantly showed that adhesion was inversely related to increasing shear stress, i.e. adhesion proved particularly increased at low shear rates.\textsuperscript{9} It is possible that variability in the expression of these molecules along the vascular tree along with differences in flow conditions might contribute to the site-specificity of thrombosis, as suggested by these authors.\textsuperscript{9} Indeed, the low-flow state in the hepatic veins compared to the portal venous system may participate in the higher frequency of PV in BCS. We also observed a statistical trend towards increased frequency of MF in PVT compared to BCS. Such difference could be due to the frequent presence of splenomegaly in MF, which may lead to external compression of the portal venous system and subsequent stasis of blood
flow. Finally, solitary JAK2V617F positive MPNs was more frequent in PVT than in BCS patients. These are new findings that deserve further evaluation in future studies.

This meta-analysis for the first time systematically assessed the diagnostic yield of JAK2V617F screening in SVT patients without typical hematological MPN features. JAK2V617F screening identified MPN in 17.1% and 15.4% of these BCS and PVT patients, respectively, which would have remained undetected prior to the JAK2V617F era. JAK2V617F was associated with subsequent development of MPNs with typical hematological MPN features in 41% and 14% of these BCS and PVT patients, respectively. These findings clearly substantiate inclusion of JAK2V617F in the routine diagnostic work-up of all SVT patients, regardless of the absence of MPN hallmarks such as elevated peripheral blood cell counts. Whether MPN specific treatment should be initiated in these patients, such as cytoreductive therapies or addition of aspirin to oral anticoagulant treatment, is a question that remains to be answered. One study described the long-term outcome of PVT patients with an underlying MPN.64 Twenty-nine and 18% of the deaths in this cohort were attributable to end-stage MF and progression to acute myeloid leukemia, respectively, indicating that risk of MPN progression is a clinical significant issue in these patients.

MPL515 mutations were reported in less than 1% of SVT patients, while the JAK2 exon 12 could not be found at all. The JAK2 exon 12 mutation has been described only once in both a PVT and BCS patient, but this was a case study.29 These results indicate that both mutations are infrequent in SVT patients, in agreement with their low frequency in MPNs compared to the JAK2V617F mutation.23-27 We therefore conclude that, unlike JAK2V617F, screening for these mutations is dispensable in the routine diagnostic approach of SVT patients.

Our analysis has several potential limitations. First, because of the rarity of both diseases, only observational studies have been published and could be included in this analysis, with their inherent risks of bias. However, a prospective design for rare thrombotic manifestations as PVT and BCS is probably unachievable. Second, a considerable heterogeneity amongst the included studies was noticed. We therefore performed all
analyses using a random-effects model, thereby accounting for between study variance, next to within study variance. In addition to the random-effects analysis, which generates a conservative estimate, we performed an analysis in which we excluded one study at a time to assess its individual impact on the results. This analysis showed that none of the included studies significantly affected the estimated prevalence of MPNs, \( JAK2V617F \), and its subtypes in both BCS and PVT. Third, diagnostic criteria for MPNs were not similar across studies. Notably, BM biopsy was not always routinely performed, which may have resulted in an underestimation of the prevalence of MPNs. Since this applies to both BCS and PVT series, the effect on the comparison between these two groups is presumably small, if at all present. Lastly, since the discovery of \( JAK2V617F \) in 2005, an increase in larger and better quality studies was observed. We therefore repeated all analyses including only publications from that point in time. In addition, we excluded papers with potential overlap of patients. The same differences between BCS and PVT were observed.

In conclusion, this meta-analysis shows a high prevalence of MPNs and \( JAK2V617F \) in SVT patients. Prevalence of \( JAK2V617F \) and MPNs in BCS are higher compared to PVT and differences in underlying MPN subtypes between these disorders exist. \( JAK2V617F \) screening identifies MPN in patients without typical hematological MPN features and should be included the routine diagnostic work-up of SVT. On the contrary, \( JAK2 \) exon 12 and \( MPL515 \) mutations are extremely rare in SVT and should not be used in the routine diagnostic approach of SVT patients. Altogether, our results are in line with the advancing insight that despite well-established similarities, marked differences in the etiology of BCS and PVT do exist.
Authorship:

J.H.S. was responsible conception and study design, collected and assembled the data, interpreted the data and wrote the paper; L.A performed data analysis; J.J.K and D.V. interpreted the data and critically revised the article for important intellectual content; H.L.A.J. assisted in study selection, analysis of results and critically revised the article for important intellectual content; F.W.G.L. was responsible for study design, selection of included studies, analysis of results and assisted on writing of the paper.

Conflict of Interest Statement:

The authors declare no competing financial interests.
REFERENCES


<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design</th>
<th>Male/female</th>
<th>Median age, y (range)</th>
<th>Median follow-up, months (range)</th>
<th>MPN criteria</th>
<th>MPN</th>
<th>JAK2V617F</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smira et al.</td>
<td>2010</td>
<td>RC</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>14/20 (70)</td>
</tr>
<tr>
<td>Zahn et al.</td>
<td>2010</td>
<td>RC</td>
<td>4/16</td>
<td>34 (14-60)*</td>
<td>NA</td>
<td>BM if MPN was suspected</td>
<td>6/20</td>
<td>(30)</td>
<td>-- 4/1/0/1/0</td>
</tr>
<tr>
<td>Darwish Murad et al.</td>
<td>2009</td>
<td>RC</td>
<td>70/93</td>
<td>38 (16-83)</td>
<td>17 (0.1-31)</td>
<td>WHO 2001, BM in majority of patients</td>
<td>56/103</td>
<td>(39)</td>
<td>35/121 (29) 27/9/2/15/3</td>
</tr>
<tr>
<td>Xavier et al.</td>
<td>2009</td>
<td>RC</td>
<td>11/20</td>
<td>33 (17-50)</td>
<td>51 (1-104)</td>
<td>WHO 2001, BM if MPN was suspected</td>
<td>8/31</td>
<td>(26)</td>
<td>8/31 (26)     4/2/0/0/2</td>
</tr>
<tr>
<td>Rajani et al.</td>
<td>2009</td>
<td>RC</td>
<td>19/24</td>
<td>40 (4-80)</td>
<td>32 (0.5-192)</td>
<td>BM in 79% of patients</td>
<td>14/36</td>
<td>(39)</td>
<td>-- 8/6/0/0</td>
</tr>
<tr>
<td>Kiladjian et al.</td>
<td>2008</td>
<td>RC</td>
<td>69/35</td>
<td>36 (IQR 27-46)</td>
<td>47 (range NA)</td>
<td>BM in nearly all patients</td>
<td>47/104</td>
<td>(45)</td>
<td>47/104 (45) 17/3/0/27/0</td>
</tr>
<tr>
<td>Colaizzo et al.</td>
<td>2008</td>
<td>RC</td>
<td>9/23</td>
<td>35 (14-66)</td>
<td>NA</td>
<td>WHO criteria 2001</td>
<td>17/32</td>
<td>(53)</td>
<td>11/32 (34) 4/1/9/2/1</td>
</tr>
<tr>
<td>Uskudar et al.</td>
<td>2008</td>
<td>RC</td>
<td>40/35</td>
<td>34 (14-72)*</td>
<td>18 (1-30)</td>
<td>BM if MPN was suspected</td>
<td>6/72</td>
<td>(8)</td>
<td>-- 5/1/0/0</td>
</tr>
<tr>
<td>De Stefano et al.</td>
<td>2007</td>
<td>RC</td>
<td>4/11</td>
<td>NA</td>
<td>48 (24-108)‡</td>
<td>PVSG 2000</td>
<td>5/15</td>
<td>(33)</td>
<td>5/15 (33) 1/3/0/0/1</td>
</tr>
<tr>
<td>Smalberg et al.</td>
<td>2006</td>
<td>RC</td>
<td>14/26</td>
<td>28 (18/53)</td>
<td>7.1 ± 6.9*</td>
<td>WHO 2001, BM in majority of patients</td>
<td>13/40</td>
<td>(33)</td>
<td>7/17 (41) 6/6/0/1/0</td>
</tr>
<tr>
<td>Patel et al.</td>
<td>2006</td>
<td>RC</td>
<td>15/26</td>
<td>36 ± 13.3</td>
<td>49 (8-87)§</td>
<td>BM in all patients</td>
<td>27/55</td>
<td>(49)</td>
<td>24/41 (59) 6/8/0/14/0</td>
</tr>
<tr>
<td>Primignani et al.</td>
<td>2006</td>
<td>RC</td>
<td>8/12</td>
<td>33 (19-72)</td>
<td>NA</td>
<td>WHO 2001, based on BM only</td>
<td>9/20</td>
<td>(45)</td>
<td>8/20 (40) 3/3/0/3/0</td>
</tr>
<tr>
<td>Eapen et al.</td>
<td>2006</td>
<td>RC</td>
<td>22/39</td>
<td>36 (16/77)</td>
<td>52 (0-181)</td>
<td>Not specified</td>
<td>17/61</td>
<td>(28)</td>
<td>-- 7/6/1/3/0</td>
</tr>
<tr>
<td>Khuroo et al.</td>
<td>2005</td>
<td>RC</td>
<td>17/23</td>
<td>27 ± 7.3*</td>
<td>NA</td>
<td>BM if MPN was suspected</td>
<td>4/40</td>
<td>(10)</td>
<td>-- 1/3/0/0/0</td>
</tr>
<tr>
<td>Darwish Murad et al.</td>
<td>2004</td>
<td>RC</td>
<td>78/159</td>
<td>35 (13/76)</td>
<td>44 (0-203)</td>
<td>BM if MPN was suspected</td>
<td>54/237</td>
<td>(23)</td>
<td>-- 45/9/0/0/0</td>
</tr>
<tr>
<td>Atwell et al.</td>
<td>2004</td>
<td>RC</td>
<td>7/15</td>
<td>24 (18-68)*</td>
<td>NA</td>
<td>BM if MPN was suspected</td>
<td>11/22</td>
<td>(50)</td>
<td>-- 8/3/0/0/0</td>
</tr>
<tr>
<td>Janssen et al.</td>
<td>2000</td>
<td>CC</td>
<td>16/27</td>
<td>40 (19-60)</td>
<td>NA</td>
<td>BM if MPN was suspected</td>
<td>12/43</td>
<td>(28)</td>
<td>-- 10/1/0/1/0</td>
</tr>
<tr>
<td>Denninger et al.</td>
<td>2000</td>
<td>RC</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>BM if MPN was suspected</td>
<td>12/32</td>
<td>(38)</td>
<td>-- 12/0/0/4/0</td>
</tr>
<tr>
<td>Mahmoud et al.</td>
<td>1996</td>
<td>RC</td>
<td>17/27</td>
<td>37 (19-60)*</td>
<td>NA</td>
<td>BM if MPN was suspected</td>
<td>17/42</td>
<td>(40)</td>
<td>-- 11/5/1/0/0</td>
</tr>
</tbody>
</table>

Abbreviations: RC, retrospective cohort; CC, case-control; MPN, Myeloproliferative neoplasm; PV, polycythemia vera; ET, essential thrombocytosis; MF, myelofibrosis; U, unclassifiable; SolitaryJAK2, SolitaryJAK2 positive; NA, not available; IQR, interquartile range; BM, bone marrow biopsy.  
*Mean age/follow-up (range) or ± standard deviation.  
†MPNs that became overt during follow up were included in subtype analysis.  
‡Median follow-up of patients with JAK2V617F-positive MPN without elevated blood counts  
§Median time of diagnosis to overt MPN.
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design</th>
<th>Male/ Female</th>
<th>Median age (range)</th>
<th>Median follow-up months (range)</th>
<th>MPN criteria</th>
<th>MPNs</th>
<th>JAK2V617F</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoekstra et al.</td>
<td>2011</td>
<td>RC</td>
<td>13/31</td>
<td>48 (18-79)</td>
<td>70 (5-252)</td>
<td>WHO 2008 criteria</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Rajani et al.</td>
<td>2010</td>
<td>RC</td>
<td>80/93</td>
<td>57 (15-94)</td>
<td>30 (0-116)</td>
<td>Not specified, BM in majority of patients</td>
<td>15/89 (17)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Orr et al.</td>
<td>2010</td>
<td>RC</td>
<td>14/21</td>
<td>43 (18/72)</td>
<td>51 (10-300)</td>
<td>WHO 2001, BM if MPN was suspected</td>
<td>6/35 (17)</td>
<td>16/35 (46)</td>
<td>2/3/1/1/98</td>
</tr>
<tr>
<td>Plessier et al.</td>
<td>2010</td>
<td>RC</td>
<td>50/52</td>
<td>48 ((16/84)</td>
<td>20 (0-75)</td>
<td>WHO 2001, BM in majority of patients</td>
<td>17/102 (17)</td>
<td>14/82 (17)</td>
<td>3/11/3/2/2</td>
</tr>
<tr>
<td>Xavier et al.</td>
<td>2009</td>
<td>RC</td>
<td>40/37</td>
<td>42 (17-74)</td>
<td>51 (1-104)</td>
<td>WHO 2001, BM if MPN was suspected</td>
<td>3/76 (4)</td>
<td>15/76 (20)</td>
<td>1/3/2/1/8</td>
</tr>
<tr>
<td>Kiladjian et al.</td>
<td>2008</td>
<td>RC</td>
<td>77/60</td>
<td>42 (IQR 30-57)</td>
<td>66 (range NA)</td>
<td>Not specified, BM in nearly all patients</td>
<td>48/137 (28)</td>
<td>47/137 (34)</td>
<td>14/8/3/230</td>
</tr>
<tr>
<td>Bayraktar et al.</td>
<td>2008</td>
<td>RC</td>
<td>9/16</td>
<td>45 (24-73)*</td>
<td>NA</td>
<td>WHO, BM if MPN was suspected</td>
<td>6/25 (24)</td>
<td>6/25 (24)</td>
<td>3/2/1/0/5</td>
</tr>
<tr>
<td>Colaizzo et al.</td>
<td>2007</td>
<td>RC</td>
<td>27/31</td>
<td>NA</td>
<td>48 (24-108)‡</td>
<td>PVSG 2000</td>
<td>8/58 (14)</td>
<td>24/58 (41)</td>
<td>4/5/0/15</td>
</tr>
<tr>
<td>McMahon et al.</td>
<td>2007</td>
<td>RC</td>
<td>9/1</td>
<td>NA</td>
<td>NA</td>
<td>Not specified</td>
<td>0/10 (0)</td>
<td>1/10 (10)</td>
<td>0/0/0/0/1</td>
</tr>
<tr>
<td>Primignani et al.</td>
<td>2006</td>
<td>RC</td>
<td>29/44</td>
<td>42 (13-66)</td>
<td>NA</td>
<td>WHO 2001, based on BM only</td>
<td>31/55 (56)</td>
<td>26/73 (36)</td>
<td>5/14/5/9/0</td>
</tr>
<tr>
<td>Kocher et al.</td>
<td>2005</td>
<td>RC</td>
<td>10/10</td>
<td>51 (17-83)</td>
<td>21 (2-61)</td>
<td>Not specified, BM if MPN was suspected</td>
<td>6/20 (30)</td>
<td>--</td>
<td>2/4/0/0/0</td>
</tr>
<tr>
<td>Janssen et al.</td>
<td>2001</td>
<td>RC</td>
<td>NA</td>
<td>NA</td>
<td>3.9 (0.1-13.1)*</td>
<td>Not specified, BM if MPN was suspected</td>
<td>22/82 (27)</td>
<td>--</td>
<td>12/2/5/2/0§</td>
</tr>
<tr>
<td>Denninger et al.</td>
<td>2000</td>
<td>RC</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Not specified, BM if MPN was suspected</td>
<td>5/36 (14)</td>
<td>--</td>
<td>5/0/0/6/0</td>
</tr>
<tr>
<td>Valla et al.</td>
<td>1988</td>
<td>RC</td>
<td>14/17</td>
<td>NA</td>
<td>NA</td>
<td>Not specified, BM if MPN was suspected</td>
<td>7/31 (23)</td>
<td>--</td>
<td>2/1/2/0/0</td>
</tr>
</tbody>
</table>

Abbreviations: RC, retrospective cohort MPN; Myeloproliferative neoplasm; PV, polycythemia vera; ET, essential thrombocytosis; MF myelofibrosis; U, unclassifiable; Solitary JAK2, Solitary JAK2 positive; NA, not available; IQR, interquartile range; BM, bone marrow biopsy.

*Mean age/follow-up (range) was reported.
†MPNs that became overt during follow up were included in subtype analysis.
‡Median follow-up of patients with JAK2V617F-positive MPN without elevated blood counts.
§In each of these studies also one patient with chronic myeloid leukemia was reported.
Figure 1. Flow diagram study selection process.

713 studies screened by title and abstract

665 studies excluded after title and abstract reading, including reviews and editorials

48 studies retrieved for detailed evaluation

Additional identified studies:
- 5 studies from bibliographies

Inclusion criteria not met:
- Malignancies/cirrhosis not excluded (n=2)
- Selected cohorts (n=5)
- SVT not subdivided in BCS/PVT (n=1)
- MPN criteria unaccepted/unclear (n=4)
- < 10 patients included (n=2)
- Duplicate data (n=7)

32 studies included in analysis
Legends to the figures 2 and 3.

**Figure 2.** Forest plots showing the mean prevalence of MPNs (a) and JAK2V617F (b) in patients with Budd-Chiari syndrome.

**Figure 3.** Forest plots showing the mean prevalence of MPNs (a) and JAK2V617F (b) in patients with portal vein thrombosis.
Figure 2

A. MPNs in patients with Budd-Chiari syndrome

<table>
<thead>
<tr>
<th>Study</th>
<th>Pubyear</th>
<th>Event rate and 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smaïberg et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Patel et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Primignani et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>DeStefano et al.</td>
<td>2007</td>
<td></td>
</tr>
<tr>
<td>Kladjian et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Colaizzo et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Xavier et al.</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>Darwish Murad et al.</td>
<td>2009</td>
<td></td>
</tr>
</tbody>
</table>

B. JAK2V617F in patients with Budd-Chiari syndrome

<table>
<thead>
<tr>
<th>Study</th>
<th>Pubyear</th>
<th>Event rate and 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smaïberg et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Patel et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Primignani et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>DeStefano et al.</td>
<td>2007</td>
<td></td>
</tr>
<tr>
<td>Kladjian et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Colaizzo et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Xavier et al.</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>Darwish Murad et al.</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>Smira et al.</td>
<td>2010</td>
<td></td>
</tr>
</tbody>
</table>
Figure 3

A. MPNs in patients with portal vein thrombosis

<table>
<thead>
<tr>
<th>Study</th>
<th>Pubyear</th>
<th>Event Rate and 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colaiizzo et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Primignani et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>DeStefano et al.</td>
<td>2007</td>
<td></td>
</tr>
<tr>
<td>McMahon et al.</td>
<td>2007</td>
<td></td>
</tr>
<tr>
<td>Kiladjian et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Bayraktar et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Xavier et al.</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>Orr et al.</td>
<td>2010</td>
<td></td>
</tr>
<tr>
<td>Plessier et al.</td>
<td>2010</td>
<td></td>
</tr>
</tbody>
</table>

B. JAK2V617F in patients with portal vein thrombosis

<table>
<thead>
<tr>
<th>Study</th>
<th>Pubyear</th>
<th>Event Rate and 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colaiizzo et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>Primignani et al.</td>
<td>2006</td>
<td></td>
</tr>
<tr>
<td>DeStefano et al.</td>
<td>2007</td>
<td></td>
</tr>
<tr>
<td>McMahon et al.</td>
<td>2007</td>
<td></td>
</tr>
<tr>
<td>Kiladjian et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Bayraktar et al.</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td>Xavier et al.</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>Orr et al.</td>
<td>2010</td>
<td></td>
</tr>
<tr>
<td>Plessier et al.</td>
<td>2010</td>
<td></td>
</tr>
</tbody>
</table>
Appendix: Medline Search Strategy

Date: August 1st, 2011
Database: Medline
Limits: English, limits publication date 01/01/1980-01/08/2010

1. Myeloproliferative disorders [Mesh]: 23690
2. Myeloproliferative neoplasms: 2798
3. Janus Kinase 2 [Mesh]: 2880
4. MPL protein, human [Substance Name]: 503
5. Colony-Forming Units Assay: 13111
6. Budd-Chiari Syndrome [Mesh]: 1539
7. Hepatic vein thrombosis: 2885
8. Hepatic venous thrombosis: 1544
9. Hepatic outflow obstruction: 295
10. Vascular liver disease: 11915
13. Portal vein thrombosis: 3158
15. Splanchnic vein thrombosis: 206
16. Splanchnic venous thrombosis: 163
17. Abdominal vein thrombosis: 2091
18. Abdominal venous thrombosis: 1587
19. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18: 19561
20. 1 and 19: 214
21. 2 and 19: 45
22. 3 and 19: 57
23. 4 and 19: 3
24. 5 and 19: 12
25. 20 or 21 or 22 or 23 or 24: 255

The search was supplemented by manually reviewing the reference list of retrieved articles.
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis